The phannacokinetics of cefotaxime, moxalactam, and ceftazidime were investigated in six human volunteers who received in a crossover fashion doses of 0.5, 1.0, and 2.0 g of each drug by a 5-min infusion. Doses of 1.0 g were repeated after the administration of probenecid. Serum and urine concentrations were assayed with an agar diffusion method. Serum concentrations of moxalactam exceeded those of ceftazidime at all times and were distinctly higher than those of cefotaxime. The normalized area under the concentration time curve (defined as the ratio of the area under the curve per dose) reflects this relationship: compared with cefotaxiine the nornalized area under the curve of moxalactam was 3 to 4 times higher, and that of ceftazidime was 2 to 3 times higher. By intra-individual comparisons, the area under the curve of moxalactam was 44% larger than that of ceftazidime. With increasing doses, cefotaxime exhibited a nonlinear increase of the area under the curve. The half-lives of moxalactam, ceftazidime, and cefotaxime were 2.34, 1.95, and 1.16. h, respectively. The volume of distribution averaged 0.20 ± 0.03, 0.23 ± 0.02, and 0.25 ± 0.04 liters per kg, and the mean total body clearance was 84, 131, and 328 ml/min for moxalactam, ceftazidime, and cefotaxime, respectively. The 24-h urinary recovery was highest for moxalactam (75 ± 4%) followed by ceftazidime (68 ± 11%) and cefotaxime (53 ± 6%). The influence of probenecid on serum concentrations, half-life, area under the curve, and clearance was most apparent with cefotaxime, whereas the pharmacokinetics of moxalactam and ceftazidime were only slightly affected. After the 0.5-and 2.0-g doses of cefotaxime, desacetyl-cefotaxime activity (determined by high-pressure liquid chromatography) reached a peak of 2.7 and 9.9 ,ug/ml and declined with a half-life of 1.9 and 1.4 h. The ratio of the R(-) and S(-) epimers of moxalactam, which could be differentiated by high-pressure liquid chromatography, fell rapidly from 0.81 at 0.17 h to 0.5 at 5 h, indicating the presence of twice as much of the microbiologically less active S(-) epimer. From a pharmacokinetic standpoint it appears reasonable to conclude that moxalactam and possibly ceftazidime could be administered twice daily and that cefotaxime could be administered three or even four times daily.
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Cefotaxime (CTX), moxalactam (MOX), and ceftazidime (CAZ) (GR-20263) are semisynthetic parenteral cephalosporins with relatively high activities against gram-negative organisms and considerable stability against their fl-lactamases (4, 5, 8, 11) . Despite quantitative differences in activity against certain species, their antimicrobial spectra are very similar. Therefore, differences in pharmacokinetic behavior may well be a decisive factor in the physicians' choice of any of these three compounds.
The purposes of the present study were to: (i) At intervals of 2 weeks 0.5, 1.0, and 2.0 g of CTX and MOX were administered by a 5-min intravenous infusion in crossover fashion to each participant. The infusion rate was controlled with an infusion pump (Perfusor E+2; Braun Melsungen, West Germany). The 1.0-g doses were repeated after five doses of oral probenecid (0.5 g every 6 h on the day before the study and 1.0 g 30 min before the dose). Four months later the same doses of CAZ were administered under the same study protocol.
During each study blood samples were drawn through an indwelling winged needle placed in the forearm contralateral to the infusion site at 0, 0.17, 0.33, 0.5, 0.67, 0.83, 1, 1.5, 2, 3, 4, 5, 6, 7, 8, 10, and 12 h. Blood specimens were centrifuged at 4°C after clotting at room temperature. In addition, urine was collected quantitatively over six time intervals (-24 through 0, 0 through 2, 2 through 4, 4 through 8, 8 through 12, and 12 through 24 h after administration).
The exact amount of antibiotic administered to each volunteer was determined ( Fig. 1 and 2 (15, 16) . Its sensitivity limit is >1 itg/ml, and the 95% confidence limits are '15%. In addition, the comparison of the agar diffusion and the HPLC assays permitted an estimate of the accuracy of the two methods. The latter provided information on the behavior of DES-CTX and the two naturally occurring epimers of MOX. HPLC analyses were performed by R. Wise, Birmingham, United Kingdom.
Before, during, and after each study period the following tests were performed: complete blood count, urea, serum and urine creatinine, total protein, bilirubin, transaminases, alkaline phosphatase, and urinalysis. Volunteers were questioned about side effects after each study.
Pharmacokinetic analysis. A two-compartment open model was used to describe the serum concentration time courses (3) . The pharmacokinetic parameters of the model, volume of distribution of the central compartment (VO), rate constants of transfer between the two compartments (kl2 and k2l), and rate constant of elimination (ke) were adapted to the experimental data with a nonlinear fitting program by minimizing the sum of weighted squared deviations (7) . The weighting function of the residuals between observed and predicted values was derived from the analysis of precision of the bioassay which yielded a constant relative error. The terminal half-life (t1/2) was then defined by these parameters. The total volume of distribution (VD), total body clearance (CIB), and total renal clearance (CIR) were calculated by the following equations: VD= V1 (1 + k12/k2l), CIB = Vike, and CIR = CIBfeU, where feU is the excreted urinary fraction of the administered dose. The areas under the serum concentration time curves (AUC) were estimated by the trapezoidal rule. To facilitate comparisons among the various doses and drugs, AUCs were normalized by dividing through the individual doses. For all statistical evaluations the Wilcoxon matchedpairs signed rank test was used. Probabilities of 2a X0.05 were considered significant.
Because of inappropriate infusion in one of 72 drug administrations the data from one volunteer who was given the 2.0-g dose of CAZ were excluded from the above calculations.
RESULTS
Serum kinetics by bioassay analysis. The mean serum concentrations of CTX, MOX, and CAZ are presented in Fig. 1 and 2. At 6, 8, and 12 h serum concentrations of CTX were frequently below the lowest standard (0.125 ,ug/ml). (Fig. 3) .
Pharmacokinetic parameters. In contrast to MOX and CAZ, several serum concentration time curves of CTX did not exhibit a biexponential decline, suggesting that a two-compartment pharmacokinetic model would not describe all experimental data sets adequately. This phenomenon occurred independently of the administered dose, was observed in all volunteers at least for one dose, and, with the exception of the 1.0-g dose of one volunteer (Fig. 4) , could not unambiguously be identified as a triexponential decline. This figure is an example of the unusual pharmacokinetic behavior of CTX and serves to illustrate the problem of correctly defining the elimination half-life. A two-compartment model was applied to fit the data of the 2.0-and 1.0-g doses. No systematic deviations between observed and predicted data points were seen for the 2.0-g dose. This is in contrast to the 1.0-g dose, where serum concentrations were initially fitted in the time period between 0 and 6 h and subsequently fitted between 0 and 10 h (Fig. 4) . Inclusion of the 7-, 8-, and 10-h data points into the computer fit prolonged the half-life from 1 h to over 3 h. The problem of defining a realistic half life is summarized in Fig. 5 . All individual curves were fitted three times: once by incorporating the data of the first 5 h only, a second time by additionally including the 6-h values, and a third time by incorporating all data for the time periods of 7, 8, 10 , or 12 h depending on the number of available measurements above the sensitivity limit of the assay. Figure 5 clearly demonstrates that the half-life of CTX was prolonged as the time period of the computer-fitted data points was increased.
With this nonlinear behavior of CTX ( Fig. 3  and 5 ) the question arises of whether an acceptable quantification results from linear analysis. When a two-compartment open model was fitted to CTX serum data of the first 6 h only, the relative differences between measured and cal- (17) . The antimicrobial activity of R(-) is approximately doubled compared with that of S(-) (15) . HPLC allows differentiation between the two epimers (15) . Figure 7 shows the mean ratio of the concentrations of R(-) and S(-) after intravenous administration of 2.0 and 0.5 g of MOX. The R/S ratio of 0.84 10 min after injection fell to 0.5 at 5 h (2.0-g dose), indicating the presence of twice as much of the S(-) epimer compared with R(-). The decline of the mean ratio for the 0.5-g dose was similar but less uniform.
Serum kineticds of CTX and DES-CTX determined by HPLC. Desacetylation of CTX occurred rapidly in vivo (Fig. 8) life which is necessary to calculate the terminal portion of the AUC. Nevertheless, the data obtained with the HPLC and agar diffusion method agreed reasonably well (Table 2 and Fig.  3 ). After the 2.0-g dose the AUC for the desacetyl metabolite was 18 ± 2% of the total area of CTX; for the 0.5-g dose this proportion increased to 31 ± 12%, suggesting that desacetylation may not follow first-order kinetics.
Comparison of the HPLC and the agar diffusion method. The serum concentrations of CTX and MOX (0.5-and 2.0-g doses) which
were measured by both microbiological and HPLC assay were compared. The correlation coefficients for the two methods were 0.978 for CTX and 0.955 for MOX. Despite this excellent agreement, a significant difference between bioassay and HPLC results of MOX was observed (paired t-test: P < 0.001). As Fig. 9 shows, serum concentrations of MOX measured by the agar diffusion method were systematically lower than values obtained with HPLC analysis. The relative difference increased progressively during the first 2 h and remained constant thereafter (mean difference, -26%). This is probably due to the increasing proportion of the S(-) epimer of MOX (Fig. 7) which is microbiologically less active than the R(-) epimer.
No side effects were recorded throughout the entire study, and chemistry profiles, blood counts, urinalysis, and creatinine clearances remained within normal limits.
DISCUSSION
Several published studies have defined the phannacokinetic properties of CTX, MOX, and CAZ in human volunteers (2, 6, 8, 9, 12, 13 Fig. 1 and 2 ). Despite the difficulties of making an exact comparison, no relevant differences between our study and the results published in the literature were observed (2, 8, 9, 12, 13 20 and 25% of the body weight comparable to values for most cephalosporins which bind to a similar degree to serum protein (6, 8, 12) .
The dose response analyzed by AUC and total body and renal clearance versus dose showed that with increasing doses of CTX the AUC rose in a nonlinear fashion while clearance decreased.
The same phenomenon was observed previously in a study in which the pharmnacokinetics of CTX were analyzed during steady-state infusions at three different dose levels (6) . A saturation of the tubular secretory mechanisms which would become operative with sustaining infusions of 1.0 and 2.0 g per h was then postulated. The assumption of tubular secretion of CTX was confirmed by administration of probenecid in the present study. It became evident that even with the recommended doses of 0.5 to 2.0 g an increasing saturation of tubular secretion can be observed. This would suggest that doses of 0.5 g of CTX are less economical from a pharmacokinetic standpoint than 1-or even 2-g doses. This non-linearity of the dose response was not observed with the other two compounds. The influence of probenecid on serum concentration, half-life, AUC, volume of distribution, and clearance was most obvious with CTX. Saturation of tubular secretion led to serum concentrations with the 1.0-g dose of CTX which as early as 2 h were higher than those achieved with a 2.0-g dose without probenecid. Similarly, the renal clearance of this drug was decreased by almost 50% and the AUC doubled when probenecid was administered. Therefore, considerable savings could be gained with concomitant administration of probenecid. This is again in contrast to MOX and CAZ, for which the influence of this agent is of no practical significance.
Compared with that of other ,B-lactam antibiotics, urinary recovery of CTX was unusually low. This may be explained by the fact that the assay strain used in our study measured the original compound only. However, Fu et al. have demonstrated the presence of the desacetyl metabolite of CTX in urine by HPLC (2) . Even though the latter is considerably less active in vitro than the parent compound it can be assumed that urinary concentrations of CTX and DES-CTX are sufficient to treat urinary tract infections caused by even moderately susceptible pathogens (10, 14) .
The determination of serum levels of MOX and CTX by HPLC provided an opportunity to study the pharmacokinetics of DES-CTX and the behavior of the two epimers of MOX. The metabolism of CTX which occurs in vivo probably accounts at least in part for the frequently and randomly observed deviations from a twocompartment model of behavior. It appears that this metabolism cannot be described adequately by a first-order process. This is demonstrated by the relative difference in AUCs of DES-CTX for the 0.5-and 2.0-g doses. Furthermore, simultaneous simulation of the serum kinetics of CTX and its metabolite with a pharmacokinetic model which incorporated first-order desacetylation did not result in satisfactory fits of the two concentration time curves (unpublished observations). Additional studies are necessary to define the extent and rate of desacetylation to avoid accumulation of DES-CTX in patients with renal disease (10) .
At present it is difficult to speculate on the clinical relevance of differentiating between the two epimers of MOX. This study showed that there was a systematic difference between results obtained with bioassay and HPLC procedures. This difference increased as the R/S ratio decreased from an initial value of 0.84 to 0.5 at approximately 4 h after injection, when the concentration of the S(-) epimer, which has approximately 50% of the antimicrobial activity of the R(-) epimer, was doubled (15) . Consequently, the activity of MOX, measured by bioassay, was reduced by one-fourth compared with results obtained by HPLC analysis.
The comparison between the two assay methods, performed blindly in two different locations, documents a very satisfactory interlaboratory agreement. The precision of the agar diffusion method, expressed as the mean coefficient of variation determined from 165 spiked serum and phosphate-buffered saline samples, was 4.6 + 0.9%. It was fairly constant over the entire range of concentrations and did not show significant differences among the three antibiotics. The excellent agreement for the two assay methods of CTX is illustrated in Fig. 9 , which documents that the P. morganii strain virtually measures intact CTX only.
CTX, MOX, and CAZ are three new semisynthetic cephalosporins with extraordinary activity against gram-negative organisms. Despite quantitative differences, their in vitro performance is comparable. However, we demonstrated significant differences in their pharmacokinetic behavior. The term "favorable pharmacokinetics" has been applied to a variety of new antimicrobial agents. If it has any clinical relevance in the treatment of patients, MOX and CAZ would probably qualify for such a label due to their long half-lives. It will be interesting to compare the clinical efficacy of these two compounds with favorable pharmacokinetics versus one with less favorable pharnacokinetics.
